信迪利单抗联合含铂化疗治疗晚期NSCLC患者的疗效及对血清Notch1、Dickkopf-1水平的影响OA
The Efficacy of Sintilimab Combined with Platinum-based Chemotherapy in the Treatment of Advanced NSCLC Patients and Its Influence on Serum Notch1 and Dickkopf-1 Levels
目的 观察信迪利单抗联合含铂化疗治疗晚期非小细胞肺癌(NSCLC)患者的疗效及对血清 Notch1、Dickkopf-1 水平的影响.方法 选取晚期 NSCLC患者106 例,采用随机数字表法分为两组.单一组给予含铂化疗方案治疗,联用组给予信迪利单抗联合含铂化疗治疗.比较两组客观缓解率、Dickkopf-1、疾病控制率、T淋巴细胞亚群、肿瘤标志物、Notch1 mRNA 以及不良反应发生率.结果 联用组疾病控制率高于单一组(P<0.05),两组客观缓解率比较,差异无统计学意义(P>0.05).两组治疗前研究相关指标比较,差异无统计学意义(P>0.05).两组治疗3 个疗程后 Notch1 mRNA、Dickkopf-1较治疗前降低,且联用组治疗3个疗程后低于单一组(P<0.05).联用组治疗3个疗程后CD3+、CD4+以及CD4+/CD8+高于治疗前和单一组治疗3个疗程后,CD8+低于治疗前和单一组治疗3 个疗程后(P<0.05).单一组 T淋巴细胞亚群治疗前后比较,差异无统计学意义(P>0.05).两组治疗 3 个疗程后糖类抗原 125(CA125)、鳞状细胞癌抗原(SCCA)、癌胚抗原(CEA)较治疗前降低,且联用组治疗 3 个疗程后低于单一组(P<0.05).两组不良反应发生率(单一组3.77%,联用组7.55%)比较,差异无统计学意义(P>0.05).结论 信迪利单抗联合含铂化疗治疗晚期 NSCLC可改善免疫功能,抑制 Notch1、Dickkopf-1以及肿瘤标志物表达,提高客观缓解率.
Objective To observe the efficacy of sintilimab combined with platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC)patients and its impact on serum Notch1 and Dickkopf-1 levels.Methods A total of 106 patients with advanced NSCLC admitted from selected and randomly divided into two groups using a random number table.The single group was treated with platinum-based chemotherapy,while the combination group was treated with sintilimab combined with platinum-based chemotherapy.The objective response rate,disease control rate,Notch1 mRNA,Dickkopf-1,T lymphocyte subsets,tumor markers,and adverse reaction rates were compared between the two groups.Results The disease control rate was higher in the combination therapy group than in the single-agent group(P<0.05).There was no significant difference in objective response rates between the two groups(P>0.05).Pre-treatment study-related indicators showed no significant differences between the two groups(P>0.05).After three treatment cycles,both groups showed decreased Notch1 mRNA and Dickkopf-1 levels compared to baseline.The combined therapy group exhibited lower levels than the single-agent group after three cycles(P<0.05).After three treatment cycles,the combined therapy group exhibited higher CD3+,CD4+,and CD4+/CD8+ratios compared to pre-treatment levels and the monotherapy group after three cycles.Conversely,CD8+levels were lower than pre-treatment and monotherapy group levels after three cycles(P<0.05).No significant differences were observed in T lymphocyte subsets between monotherapy groups before and after treatment(P>0.05).After three treatment cycles,both groups showed decreased levels of carbohydrate antigen 125(CA125),squamous cell carcinoma antigen(SCCA),and carcinoembryonic antigen(CEA)compared to baseline.The combined therapy group exhibited lower levels than the single-therapy group after three cycles(P<0.05).The incidence of adverse reactions was comparable between groups(3.77%in the single-agent group vs.7.55%in the combination group;P>0.05).Conclusion Sintilimab combined with platinum-based chemotherapy in the treatment of advanced NSCLC can improve immune function,inhibit the expression of Notch1,Dickkopf-1,and tumor markers,and increase the objective response rate.
康丽花;翟凤钰;刘月芬
濮阳油田总医院肿瘤科,河南 濮阳 457000濮阳油田总医院肿瘤科,河南 濮阳 457000濮阳油田总医院肿瘤科,河南 濮阳 457000
医药卫生
信迪利单抗化疗非小细胞肺癌T淋巴细胞亚群肿瘤标志物
SintilimabChemotherapyNon-small cell lung cancerT lymphocyte subsetsTumor markers
《哈尔滨医药》 2026 (1)
20-24,5
评论